+

WO2000057919A3 - Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire - Google Patents

Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire Download PDF

Info

Publication number
WO2000057919A3
WO2000057919A3 PCT/CA2000/000319 CA0000319W WO0057919A3 WO 2000057919 A3 WO2000057919 A3 WO 2000057919A3 CA 0000319 W CA0000319 W CA 0000319W WO 0057919 A3 WO0057919 A3 WO 0057919A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
mediated immunity
inducing cell
based artificial
particles
Prior art date
Application number
PCT/CA2000/000319
Other languages
English (en)
Other versions
WO2000057919A2 (fr
Inventor
Masanobu Sugimoto
Max Arella
Yasuhiro Furuichi
Original Assignee
Sapientia Therapeutics Ltd
Agene Res Inst
Masanobu Sugimoto
Max Arella
Yasuhiro Furuichi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapientia Therapeutics Ltd, Agene Res Inst, Masanobu Sugimoto, Max Arella, Yasuhiro Furuichi filed Critical Sapientia Therapeutics Ltd
Priority to EP00912299A priority Critical patent/EP1165142A2/fr
Priority to AU34125/00A priority patent/AU3412500A/en
Publication of WO2000057919A2 publication Critical patent/WO2000057919A2/fr
Publication of WO2000057919A3 publication Critical patent/WO2000057919A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des particules artificielles immunogènes (1), leurs procédés de production et leurs applications. Ces particules immunogènes (1) renferment une matrice à base lipide (3), des glycolipides (5, 6) et des conjugués peptide-lipide (7, 8) incrustés dans la matrice (3). Ces particules (1) sont très efficaces dans l'induction de l'immunité à médiation cellulaire (IMC) lors de leur administration chez un hôte. Les particules immunogènes (1) peuvent être utilisées comme agents immunostimulants (notamment des vaccins) et comme agents immunothérapeutiques servant à prévenir et/ou traiter des maladies infectieuses et des cancers, maladies pour lesquelles les réponses IMC jouent un rôle important.
PCT/CA2000/000319 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire WO2000057919A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00912299A EP1165142A2 (fr) 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire
AU34125/00A AU3412500A (en) 1999-03-25 2000-03-23 Lipid-based artificial particles inducing cell-mediated immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27605799A 1999-03-25 1999-03-25
US09/276,057 1999-03-25

Publications (2)

Publication Number Publication Date
WO2000057919A2 WO2000057919A2 (fr) 2000-10-05
WO2000057919A3 true WO2000057919A3 (fr) 2001-02-08

Family

ID=23054967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000319 WO2000057919A2 (fr) 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire

Country Status (3)

Country Link
EP (1) EP1165142A2 (fr)
AU (1) AU3412500A (fr)
WO (1) WO2000057919A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010084A2 (fr) * 2005-07-15 2007-01-25 Johannes Savolainen Oligosaccharides et polysaccharides immunostimulateurs et utilisations correspondantes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366058A2 (fr) * 1988-10-27 1990-05-02 Abbott Laboratories Dispositif de délivrance à libération contrôlée, procédé de préparation du dispositif et méthode d'utilisation du dispositif
WO1998016240A1 (fr) * 1996-10-15 1998-04-23 The Liposome Company, Inc. Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes
US5951986A (en) * 1993-06-09 1999-09-14 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366058A2 (fr) * 1988-10-27 1990-05-02 Abbott Laboratories Dispositif de délivrance à libération contrôlée, procédé de préparation du dispositif et méthode d'utilisation du dispositif
US5951986A (en) * 1993-06-09 1999-09-14 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
WO1998016240A1 (fr) * 1996-10-15 1998-04-23 The Liposome Company, Inc. Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIDS RESEARCH AND HUMAN RETROVIRUSES, (1994) 10 SUPPL 2 S99-103. REF: 14 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; GOULD-FOGERITE S ET AL: "Lipid matrix -based subunit vaccines: a structure-function approach to oral and parenteral immunization.", XP002150859, retrieved from STN Database accession no. 95169526 *
SUGIMOTO, MASANOBU ET AL: "Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity", FEBS LETT. (1995), 363(1,2), 53-6, XP002150858 *

Also Published As

Publication number Publication date
EP1165142A2 (fr) 2002-01-02
WO2000057919A2 (fr) 2000-10-05
AU3412500A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
IL145982A0 (en) Vaccines
GB0025577D0 (en) Vaccine
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
DK1163002T3 (da) Polykationiske kulhydrater som immunstimulanser i vacciner
EP1880735A3 (fr) Vaccin
AUPP807399A0 (en) Improved immunogenic lhrh composition and methods relating thereto
EP0914153B8 (fr) Vaccins dct-polio multivalents
PT2184071T (pt) Solubilização de polisacáridos capsulares e vacinas combinadas
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
PL1835939T3 (pl) Skoniugowane szczepionki przeciwko meningokokom
IL154913A0 (en) Composition comprising immunogenic microparticles
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2001097841A3 (fr) Qs-21 et il-12 utilises comme combinaison d'adjuvants
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2238597A (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
EP2272531A3 (fr) Intégration du vaccin conjugué de méningococcus
IL149471A0 (en) Vaccines for mycoplasma bovis and methods for immunizing bovine amimals
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
FR2798291B1 (fr) Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
CA2216410A1 (fr) Vaccins inactives ameliores
WO2001000231A3 (fr) Vaccins
MY127452A (en) Vaccines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000912299

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000912299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000912299

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载